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ABSTRACT
Background
Statins are widely used cholesterol-lowering drugs that act by inhibiting HMGCoA reductase,
the rate-limiting enzyme in cholesterol biosynthesis. Recent evidence suggests that statin use
may be associated with a decreased risk for Alzheimer disease, although the mechanisms
underlying this apparent risk reduction are poorly understood. One popular hypothesis for
statin action is related to the drugs’ ability to activate a-secretase-type shedding of the a-
secretase-cleaved soluble Alzheimer amyloid precursor protein ectodomain (sAPPa). Statins also
inhibit the isoprenoid pathway, thereby modulating the activities of the Rho family of small
GTPases—Rho A, B, and C—as well as the activities of Rac and cdc42. Rho proteins, in turn,
exert many of their effects via Rho-associated protein kinases (ROCKs). Several cell-surface
molecules are substrates for activated a-secretase-type ectodomain shedding, and regulation
of shedding typically occurs via activation of protein kinase C or extracellular-signal-regulated
protein kinases, or via inactivation of protein phosphatase 1 or 2A. However, the possibility that
these enzymes play a role in statin-stimulated shedding has been excluded, leading us to
investigate whether the Rho/ROCK1 protein phosphorylation pathway might be involved.
Methods and Findings
We found that both atorvastatin and simvastatin stimulated sAPPa shedding from a
neuroblastoma cell line via a subcellular mechanism apparently located upstream of
endocytosis. A farnesyl transferase inhibitor also increased sAPPa shedding, as did a dominant
negative form of ROCK1. Most conclusively, a constitutively active ROCK1 molecule inhibited
statin-stimulated sAPPa shedding.
Conclusion
Together, these data suggest that statins exert their effects on shedding of sAPPa from
cultured cells, at least in part, by modulation of the isoprenoid pathway and ROCK1.
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Alzheimer disease is the leading cause of dementia among
the elderly and is characterized by accumulation of extra-
cellular and vascular amyloid in the brain [1]. Amyloid
deposits are composed of the amyloid-b peptide (Ab), a 4-kDa
peptide released during ‘‘amyloidogenic’’ proteolytic pro-
cessing of the Alzheimer Ab precursor protein (APP) [2]. APP
can also be cleaved by the nonamyloidogenic a-secretases, a
disintegrin and metalloproteinase 10 (ADAM-10) and ADAM-
17 [3], in a reaction that is believed to occur primarily on the
plasma membrane [4] and is known as ‘‘ectodomain shed-
ding.’’ a-Secretase-type ectodomain shedding divides the Ab
domain of APP, thereby generating a-secretase-cleaved
soluble APP ectodomain (sAPPa) [4]. This reaction can be
stimulated by activation of protein kinase C (PKC) or
extracellular-signal-regulated protein kinases (ERKs) [5,6,7]
or by inactivation of protein phosphatase 1 or 2A [5].
Reports from retrospective analyses suggest that the statin
class of cholesterol-lowering HMGCoA reductase inhibitors
may lower the risk for Alzheimer disease by as much as 70%
[8,9,10,11]. Studies in wild-type guinea pigs and in plaque-
forming transgenic mice have demonstrated that chronic
statin treatment can attenuate cerebral amyloidosis [12,13],
suggesting that statins may exert their risk-reducing effects,
at least in part, by modulating APP metabolism. In cell
culture, lovastatin and simvastatin decrease the release of Ab
by rat hippocampal neurons [12,14] while activating a-
secretase-type ectodomain shedding [15,16]. However, the
molecular mechanisms by which statins modulate ectodo-
main shedding remain to be elucidated [17,18].
Statin effects on APP metabolism are, to some extent,
attributable to cholesterol lowering, but statin actions on
APP may also involve cholesterol-independent actions [19].
Reduction in synthesis of mevalonate leads to decreased
generation of a number of isoprenoid lipid derivatives.
Isoprenoids, such as farnesyl pyrophosphate and geranylger-
anyl pyrophosphate, are 15- or 20-carbon lipid moieties.
Through the action of farnesyl transferases and type I
geranylgeranyl transferases, isoprenoids are attached to the
amino acid sequence Cys-Ala-Ala-Xaa (‘‘CAAX’’) at the C-
terminus of the Rho family of GTPases [20]. These
posttranslational lipid modiﬁcations are essential for attach-
ment of the GTPases to the cytosolic face of intracellular
vesicles and/or to the cytosolic leaﬂet of the plasma
membrane, thereby specifying subcellular targets for GTPase
action(s).
Some members of the Rho GTPase family exert their
actions through modulation of protein kinase activities. One
of the best characterized is Rho-associated protein kinase 1
(ROCK1, also called ROKb). ROCK1 is a serine/threonine
kinase with an apparent mass of 160 kDa that can be activated
by either RhoA or RhoB [21,22,23]. Structurally, the ROCK1
N-terminus contains the protein kinase domain, while the C-
terminus has both a Rho-binding domain and a pleckstrin
homology domain, either of which can modulate protein–
protein interactions. In the inactive state, the Rho-binding
domain and the pleckstrin homology domain form an
autoinhibitory loop by binding and blocking the kinase
domain at the N-terminus of the molecule. Activation of
ROCK1 occurs when a Rho protein binds to the Rho-binding
domain, causing a conformational change that opens the
kinase domain for the phosphorylation of downstream
effectors [23]. Once activated, ROCK1 phosphorylates several
substrates, including myosin light chain phosphatase, LIM
kinases (Lin11, Isl1, and Mec3), and ezrin-radixin-moesin
proteins [24,25,26,27]. ROCK1 has recently been implicated
in modifying the site of substrate cleavage by APP c-secretase
[28], perhaps acting via ROCK1-dependent phosphorylation
of a component of the c-secretase enzyme complex.
In the current study, we demonstrate that activation of
sAPPa shedding from cultured cells by atorvastatin or
simvastatin involves isoprenoid-mediated protein phosphor-
ylation. Treatment of cells with a farnesyl transferase
inhibitor or expression of a dominant negative (DN) ROCK1
molecule led to enhanced sAPPa shedding, supporting the
notion that shedding is modulated by the isoprenoid path-
way. Transfection with the cDNA for a constitutively active
(CA) ROCK1 molecule led to inhibition of statin-activated
sAPPa shedding. These results raise the possibility that the
apparent beneﬁcial effect of statins in the prevention of
Alzheimer disease could be, at least in part, mediated by
isoprenoid modulation of APP metabolism.
Methods
Reagents
The APP C-terminal speciﬁc polyclonal antibody 369 [29]
was used to detect full-length APP and its C-terminal
fragments. Monoclonal antibody 6E10 against residues 1–16
of human Ab (Signet, Dedham, Massachusetts, United States)
was used to detect human holoAPP or sAPPa. Anti-ROCK1
antibody was purchased from Chemicon (Temecula, Califor-
nia, United States). Streptavidin-antibody HRP-conjugated C-
Myc antibody 9E10, mevalonic acid, arachidonic acid, and
phenylarsine oxide were purchased from Sigma (St. Louis,
Missouri, United States). Atorvastatin was obtained from
Pﬁzer (Groton, Connecticut, United States), and simvastatin
was obtained from LKT Labs (St. Paul, Minnesota, United
States). N2 supplement was obtained from Gibco (Carlsbad,
California, United States). Sulfo-NHS-LC-Biotin was pur-
chased from Pierce (Rockford, Illinois, United States). CA and
DN Myc-tagged ROCK1 vectors were generated as previously
described [30,31] and were generous gifts from Liqun Luo
(Stanford University). Fugene 6 was purchased from Roche
(Basel, Switzerland). Farnesyl transferase inhibitor 1 (FTI-1)
was obtained from Biomol (Plymouth Meeting, Pennsylvania,
United States). Tumor necrosis factor a (TNFa) protease
inhibitor 2 and Y-27632 were purchased from Calbiochem
(San Diego, California, United States). Protein concentration
assay kit was purchased from Biorad (Hercules, California,
United States). LIVE/DEAD Viability/Cytotoxicity Assay Kits
and Amplex Red Cholesterol Assay Kits were purchased from
Molecular Probes (Eugene, Oregon, United States).
Culture Methods and Sample Preparation
N2a mouse neuroblastoma cells stably transfected with the
Swedish mutant form of APP (SweAPP N2a cells; APP695,
595–596 KM/NL) (gift from G. Thinakaran and S. Sisodia,
University of Chicago, Chicago, Illinois, United States) were
maintained in DMEM, 10% FBS, and 200 lg/ml G418 in the
presence of penicillin and streptomycin [32]. For the 24 h
prior to pharmacological treatments, the culture media were
changed to N2-supplemented lipid-free medium. In some
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medium 48 h before pharmacological treatments. Trans-
fections were carried out using the Fugene reagent, according
to the manufacturer’s instructions. All treatments were
performed in the presence of 1 lM mevalonic acid, unless
otherwise speciﬁed.
Cells were lysed in 1% Triton-X/PBS buffer containing 1 X
complete proteinase inhibitor cocktail (Roche), sonicated
twice for 30 s, and centrifuged at 5,000g for 5 min. Protein
concentration in the supernatant was determined using the
Biorad Protein Assay kit, following the manufacturer’s
instructions. For the detection of holoAPP and sAPPa,
samples were separated in 7.5% polyacrylamide gels, trans-
ferred to nitrocellulose, and the proteins detected with either
369 (1:3,000 for holoAPP and C-terminal fragments) or 6E10
(1:1,000 for holoAPP or sAPPa), followed by incubation of the
transfers with appropriate secondary anti-rabbit or anti-
mouse antibodies. For the detection of transfected ROCK1
proteins, samples were immunoprecipitated with 2 lg of anti-
Myc antibody, separated in 5% polyacrylamide gels, trans-
ferred, and the proteins detected with anti-ROCK1 antibody
(1:1,000 dilution).
Cell-Surface Biotinylation
Cells were plated in a 100-mm dish at a concentration of 5
3 10
6 cells/dish. After treatment, media were harvested, and
sAPPa levels were evaluated by immunoblotting as described
above. Cells were washed twice in PBS and then incubated
with Sulfo-NHS-LC-Biotin for 30 min at 4
oC. Biotinylation
reactions were terminated by one wash in Tris followed by
two washes in PBS. Cells were lysed in 1% Triton-X/PBS
buffer containing protease inhibitor cocktail as indicated
above. Lysates were immunoprecipitated with 3 ll of whole
369 antibody serum and 30 ll of protein A beads. After
washing twice with 1% Triton/PBS, and then twice with PBS,
samples were boiled in sample buffer for 3 min, separated in
a 7.5% polyacrylamide gel, and transferred to nitrocellulose.
The biotinylated proteins were detected using streptavidin
HRP polymer (1:10,000 dilution).
Viability/Cytotoxicity Assays
Cells were plated in an eight-well slide at a concentration
of 1 3 10
4 cells/well. After treatments as indicated, LIVE/
DEAD assays were performed following the manufacturer’s
instructions (Molecular Probes).
Cholesterol Assays
Cholesterol levels in cell lysates were measured using
Amplex Red following the manufacturer’s instructions
(Molecular Probes). We have previously demonstrated that
standard doses of either simvastatin or atorvastatin reduce
cholesterol levels in N2a cells by 65%–67% [16].
Quantification and Statistical Analysis
Quantiﬁcation of protein bands was performed using the
UVP Bioimaging System, and statistical analysis was per-
formed on paired observations using the Student’s t test.
Results
Atorvastatin Activates sAPPa Shedding at a Subcellular
Site Upstream of Endocytosis from the Plasma Membrane
We conﬁrmed our previous observation [16] that atorvas-
tatin produces an increase in sAPPa shedding that is dose-
dependent, reaching a maximum effect at 5 lM. The increase
in sAPPa shedding is accompanied by a corresponding
increase in levels of the nonamyloidogenic APP a-C-terminal
fragment (C83; data not shown).
In order to reﬁne our localization of the subcellular target
of statin action, we evaluated the steady-state levels of cell-
surface APP (csAPP) in the absence or presence of statins.
After drug treatments, cells were subjected to the surface
biotinylation protocol. Cells and media were harvested, and
levels of sAPPa, holoAPP, and csAPP were measured. Treat-
ment with atorvastatin increased csAPP by approximately
1.6-fold, similar to the effect of the drug on holoAPP (Figure
1), while sAPPa shedding was increased by approximately 7-
fold (p , 0.05). Since csAPP levels were only slightly raised in
the same statin-treated cells in which sAPPa shedding was
dramatically increased, we interpret this disparity to indicate
that the effector of statin-stimulated shedding is probably
intrinsic to the plasma membrane. In other studies, the
plasma membrane has been proposed to be, or to contain, the
statin target. For example, statins have been proposed to
cause co-localization of a-secretase and APP within lipid rafts
[15,33]; statins might also induce modiﬁcation of the
structure and activity of a protein in the plasma membrane
Figure 1. Atorvastatin Activates sAPPa Shedding Out of Proportion to Its
Effect on holoAPP or csAPP
(A) SweAPP N2a cells were treated with atorvastatin (Atv) for 24 h
and then surface biotinylation was performed as described in
Methods. Evaluation of csAPP was performed by immunoprecipita-
tion–immunoblot after surface biotinylation, while holoAPP and
sAPPa were evaluated by immunoblot as described in Methods. C,
control.
(B) Graphic representation of data. Y-axis shows effect of treatment
(in arbitrary units) divided by effect of untreated control (in arbitrary
units); n = 3 independent experiments; *, p , 0.05; **, p , 0.01;
Student’s t test).
DOI: 10.1371/journal.pmed.0020018.g001
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statins bind and ‘‘lock’’ cell-surface integrins [34].
A pulse-chase protocol was also used to study post-
transcriptional regulation of APP metabolsm by statins (data
not shown). This protocol avoids any confound that might
arise because of altered APP transcription. Pulse-chase
studies were performed using a 10-min pulse with [
35S]me-
thionine followed by various chase times from 0 to 120 min.
Typical maturation and half-life of mature cellular holoAPP
were observed, as was subsequent release of sAPPa [5,29]. In
the presence of either atorvastatin or simvastatin, the time
course of maturation and release perfectly paralleled that
observed in the absence of either drug, except that the
fractional content of cellular mature holoAPP was approx-
imately 2-fold greater in the presence of drug (i.e., at 15 or 75
m i nc h a s e ,m a t u r eA P Pi nt h ep r e s e n c eo fs t a t i nw a s
approximately 310% of the level of immature APP at t =0
versus a control [vehicle treatment] of 150% of the level of
immature APP at t = 0; also, at t = 30 min, the relative
percent values for drug versus vehicle were 380% and 200%,
respectively). Fold increases in released sAPPa in the same
experiments were approximately 3- to 4-fold (2.0 arbitrary
units versus 5.5–8.0 arbitrary units at 120 min for atorvastatin
and simvastatin, respectively). Secretory maturation toxicity
is one possible mechanism for elevated levels of intracellular
mature holoAPP and causes retarded conversion of mature
holoAPP to sAPPa. This pattern was not observed following
statin treatment, excluding maturation toxicity as a mecha-
nism underlying the altered levels of mature cellular
holoAPP.
Instead, the pattern that we observed raises the possibility
that statins, presumably via isoprenoids (given the reversi-
bility with mevalonate), as discussed in the next section, may
alter sorting of cellular holoAPP, diverting holoproteins away
from terminal degradation in the endosomal/lysosomal path-
way and into the constitutive secretory pathway that
generates sAPPa. However, the fold effect on reduced
intracellular turnover in the endosomal/lysosomal pathway
(or sorting out of the endosomal/lysosomal pathway and into
the constitutive secretory/shedding pathway) is apparently
insufﬁcient to explain the fold effect on sAPPa generation (2-
fold for the former, vs 3- to 4-fold for the latter), indicating a
contribution from a downstream site in the processing
pathway. When these results are taken together with
independent work on regulated shedding of transforming
growth factor a (TGFa) [35,36], a parsimonious explanation is
that an important target for activation of ectodomain
shedding is probably located at the plasma membrane or
downstream of APP residence at the plasma membrane.
The identiﬁcation of the regulatory components of the
ectodomain shedding machinery have been long-sought in
other studies employing phorbol esters to stimulate shedding
of sAPPa or TGFa [4,35,36,37]. Munc-13 has recently been
implicated as a phorbol target in regulated shedding [38]. In
our opinion, this molecule is rather unlikely to play a major
role in shedding regulation, given the speciﬁcity of Munc-13
effects for phorbols and the generalization of the regulated
shedding phenomenon to include activation by protein
phosphatase inhibitors and neurotransmitters. Neither of
these would be predicted to act via the phorbol-binding C1
domain of Munc-13.
Sisodia and colleagues [39] demonstrated that arrest of APP
endocytosis from the plasma membrane by deletion of its
NPXY clathrin-coated vesicle targeting sequence [40,41] can
dramatically stimulate sAPPa shedding, presumably by ex-
tending the half-life of co-localized a-secretase and APP on
the plasma membrane. In order to exclude the possible
contribution of altered endocytosis to statin-stimulated
shedding, we evaluated the effect of phenylarsine oxide
(PO), an inhibitor of endocytosis, on statin-stimulated
shedding (Figure 2). Treatment with either atorvastatin,
simvastatin, or PO alone increased sAPPa shedding, as
expected. Co-treatment of cells with PO plus either atorvas-
tatin or simvastatin caused stimulation of sAPPa shedding to
levels greater than the maximal levels of shedding achievable
with inhibition of endocytosis using PO alone or with
maximal doses of either statin alone (p , 0.05). The additivity
of statin- and PO-stimulated shedding is consistent with the
hypothesis that statins act at or near the plasma membrane,
prior to internalization of csAPP. Under all circumstances,
stimulated sAPPa shedding was completely blocked using
TNFa protease inhibitor 2, a standard a-secretase/metal-
loproteinase inhibitor (Figure 2). We interpret this as an
indication that the statin-induced a-cleavage of APP is
probably mediated by one of the molecules usually associated
with the phenomenon, i.e., ADAM-10 or ADAM-17 [16].
Figure 2. Simultaneous Treatment of SweAPP N2a Cells with Statins and
an Inhibitor of Endocytosis (PO) Yields More sAPPa Shedding Than Does
Treatment with Either Statins or PO Alone
(A) SweAPP N2a cells were treated for 24 h with atorvastatin (Atv) or
simvastatin (Sim) as indicated. Media were then replaced and cells
were treated for an additional 20 min with atorvastatin, simvastatin,
TNFa protease inhibitor, PO, or combinations, as indicated.
Evaluation of sAPPa and holoAPP was performed by Western blot
as described in Methods. C, control.
(B) Graphic representation of data. Y-axis shows effect of treatment
(in arbitrary units) divided by effect of untreated control (in arbitrary
units); n = 3 independent experiments; *, p , 0.05 versus control; **,
p , 0.01 versus C; #, p , 0.05 versus atorvastatin alone; ##, p , 0.05
versus simvastatin alone; Student’s t test).
DOI: 10.1371/journal.pmed.0020018.g002
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sAPPa Shedding
As discussed above, there is an established relationship
between statins and isoprenoid-modulated protein phos-
phorylation. We therefore tested the effects of FTI-1 on
statin-stimulated sAPPa shedding. FTI-1 increased the shed-
ding of sAPPa, but the combination of a statin plus FTI-1
increased sAPPa shedding to levels greater than those
achievable by using either compound alone (Figure 3; p ,
0.05). In the same experiment, levels of holoAPP were
modestly increased but, again, to an extent insufﬁcient to
account for the increase in shed sAPPa (Figure 3).
To test whether statin-activated shedding might be
attributable to a metabolite downstream of HMGCoA
reductase, cells were treated with 1 lM simvastatin, 5 lM
FTI-1, and a series of concentrations of mevalonic acid. Since
FTI-1 acts downstream of HMGCoA reductase, the stimula-
tory effect of FTI-1 on sAPPa shedding would not be
predicted to be modiﬁed by mevalonate supplementation.
Low doses (,1 lM) of mevalonic acid did not affect statin-
induced sAPPa shedding, but complete inhibition of statin-
activated sAPPa shedding was achieved with higher doses of
mevalonic acid (100 lM). As predicted, the shedding observed
following treatment with FTI-1 was not inhibited by any of
the concentrations of mevalonic acid tested (Figure 4). These
data are consistent with a role for isoprenoids in statin
control of APP metabolism in cultured cells.
Expression of ROCK-Related Molecules Modulates sAPPa
Shedding in a Bidirectional Manner
Since many isoprenoid-mediated Rho effects converge on
ROCKs, we next transfected N2a cells with cDNAs encoding
either green ﬂuorescent protein (GFP) (control), CA ROCK1,
or DN ROCK1 (Figure 5). Simvastatin caused a typical
activation of sAPPa shedding from GFP-transfected cells.
When CA ROCK1 was introduced, however, shedding of
sAPPa from both untreated and simvastatin-treated cells was
diminished (Figure 5; p , 0.05 versus GFP control).
Conversely, DN ROCK1 alone activated shedding of sAPPa.
Cellular levels of holoAPP were not affected by transfection
(Figure 5; p , 0.05 versus GFP control). In studies aimed at
independent conﬁrmation of the involvement of ROCK
activation in sAPPa shedding, we treated SweAPP N2a cells
with arachidonic acid, an activator of ROCK. As shown in
Figure 6, arachidonic acid reduced the shedding of sAPPa
without altering levels of holoAPP. Based on this series of
results, we concluded that both basal and activated sAPPa
shedding from cultured cells are controlled by ROCK activity.
In some experiments, cells were treated with Y-27632 (10
nM to 50 lM), a compound that can inhibit ROCKs. Y-27632
showed no effect on basal sAPPa release and blocked statin-
activated sAPPa shedding (data not shown). This result was
unexpected in light of the effects of DN ROCK1. Given the
internally consistent actions of DN ROCK1 and CA ROCK1,
as well as the results employing either FTI-1 or arachidonate,
we concluded that the Y-27632 result might be due to
inhibition by Y-27632 of protein kinases other than ROCK1
[23]. The possibility was also considered that cytotoxicity of
Y-27632 for the central vacuolar pathway might explain the
disparity between the effects of DN ROCK1 and those of Y-
Figure 3. Simultaneous Treatment of SweAPP N2a Cells with a Statin and
FTI-1 Causes Greater sAPPa Shedding Than Either Drug Alone
(A) SweAPP N2a cells were treated for 24 h with atorvastatin (Atv, 5
lM), simvastatin (Sim, 1 lM), FTI-1 (5 lM), or a combination of FTI-1
plus a statin. Levels of sAPPa (top panel) or holoAPP (bottom panel)
were evaluated as described in Methods. C, control.
(B) Graphic representation of data. Y-axis shows effect of treatment
(in arbitrary units) divided by effect of untreated control (in arbitrary
units); n = 3 independent experiments; *, p , 0.05 versus control; **,
p , 0.05 versus atorvastatin alone; ***, p , 0.05 versus simvastatin
alone; Student’s t test).
DOI: 10.1371/journal.pmed.0020018.g003
Figure 4. Mevalonic Acid Reverses Statin-Induced, but Not FTI-1-
Induced, sAPPa Shedding
SweAPP N2a cells were treated for 24 h with simvastatin (Sim, 1 lM),
FTI-1 (5 lM), mevalonic acid (0–100 lM), or combinations as
indicated. Levels of sAPPa were evaluated by western blot as
described in Methods. This ﬁgure is representative of the results of
two independent experiments. C, control.
DOI: 10.1371/journal.pmed.0020018.g004
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ROCK Regulation of Alzheimer APP Shedding27632, but neither impairment of intracellular APP matura-
tion nor increased apoptosis as measured by LIVE/DEAD
assay were apparent following Y-27632 treatment (data not
shown). Ultimately, we were unable to document any
explanation for the disparate results of Y-27632 and DN
ROCK1.
Discussion
The isoprenoid pathway involves lipid modiﬁcation of
various members of the Rho family of small GTPases by the
addition of either farnesyl or geranylgeranyl moieties [20,42].
Isoprenylation serves to target the GTPases to the proper
organelle membrane, where their actions often relate to
cytoskeletal dynamics and/or vesicle trafﬁcking [20,42].
ROCKs are important downstream targets of Rho (Figure
7), catalyzing the phosphorylation of effector phosphoprotein
substrates [23]. The foregoing data indicate that statin-
induced activation of APP shedding in cultured cells involves
the Rho/ROCK pathway. More speciﬁcally, the data indicate
that ROCK1 activation blocks the effects of statins on APP
ectodomain shedding, while ROCK1 blockade alone can
mimic the effect of statins on APP shedding. By extension,
these data predict that application of statins to neurons
might directly or indirectly inhibit ROCK1 activity. Evalua-
tion of this possibility will be the subject of future
investigation.
The ﬁrst evidence that APP might be a substrate for
ectodomain shedding was provided by Weidemann et al. [43]
who identiﬁed sAPPa in the cerebrospinal ﬂuid and blood.
This aspect of APP metabolism bears resemblance to the
proteolytic signal transduction pathways involved in process-
ing pro-TGFa [35,36] and Notch [44]. In the case of Notch, the
process is set in motion by the binding of a ligand to the
Notch ectodomain, triggering its release (shedding). For APP,
intracellular signal transduction appears to be more impor-
tant [2,29,45]. In early studies, the existence of the shed
ectodomain of APP was used to deduce the existence of the
proteolytic activity designated a-secretase, which has the
unusual speciﬁcity of cleaving its substrates at a proscribed
distance from the extracellular leaﬂet of the plasma mem-
brane [4,39]. Ultimately, the integral cell-surface metal-
loproteinases ADAM-10 and ADAM-17/TACE were found to
underlie a-secretase-type ectodomain shedding [3,46].
Figure 5. Structure and Expression of ROCK cDNAs, and Their Effect on
Basal and Statin-Stimulated sAPPa Shedding
(A) Graphic representation of the ROCK1 constructs. Myc, Myc tag;
KD, kinase domain; PH domain, pleckstrin homology domain; RBD,
Rho-binding domain.
(B) SweAPP N2a cells were transfected with GFP, CA ROCK1, or DN
ROCK1 for 48 h. Cells were lysed and levels of expressed ROCK1
protein evaluated by immunoprecipitation–immunoblot as described
in Methods.
(C) Model for ROCK activity modulation by Rho.
(D) SweAPP N2a cells were transfected for 48 h with control (GFP),
CA ROCK1, or DN ROCK1 cDNAs. At the end of this incubation, cells
were treated for an additional 24 h with simvastatin (Sim, 1 lM).
sAPPa and holoAPP were evaluated by immunoblot as described in
Methods.
(E) Graphic representation of data. Y-axis shows effect of treatment
(in arbitrary units) divided by effect of untreated control (in arbitrary
units); n = 3 independent experiments; *, p , 0.05 versus GFP;
Student’s t test). C, control.
DOI: 10.1371/journal.pmed.0020018.g005
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answer this question requires contemplation of the physio-
logical function of APP. APP is a type 1 integral protein that
is subjected to a host of post-translational processing events,
including N- and O-glycosylation, tyrosyl sulfation, phos-
phorylation, and proteolysis [39,43,47,48]. Most (60%–80%)
newly synthesized APP is subjected to terminal intracellular
degradation that generates no discrete fragments [5]. A
smaller fraction of APP molecules (approximately 20% in
PC12 cells under basal conditions [5]) undergoes ectodomain
shedding catalyzed by either the a-secretase (nonamyloido-
genic) or b-secretase (potentially amyloiodgenic) pathway.
When PKC is activated, the stoichiometry of shed sAPPa rises
from 2 mol shed per 10 mol synthesized to 4 mol shed per
mole synthesized. Most of this shedding is catalyzed by the a-
secretase pathway, but a trace amount (,5% [49]) is catalyzed
by b-secretase/b-site APP cleaving enzyme [50]. sAPPa and
sAPPb differ by the inclusion in sAPPa of the ﬁrst 16 residues
of Ab. Unlike sAPPa, which is generated at the plasma
membrane, most sAPPb is probably generated by cleavage
within the trans-Golgi network and endocytic pathway
vesicles. HoloAPP levels are likely limiting at one or more
sorting steps in the late secretory pathway, since activated
sAPPa shedding is apparently accompanied by diminished
generation of sAPPb [51].
What is the function of shed sAPPa? Again, from other
molecules, we know that shedding can serve important
cellular functions by releasing diffusible ligands from their
membrane-bound precursors (e.g., TGFa and TNFa)o rb y
terminating intercellular signaling (e.g., Notch). A popular
model holds that sAPPa may function as a neurotrophic and/
or neuroprotective factor, and may promote neurite out-
growth [52]. More recent evidence suggests that released APP
derivatives modulate efﬁcacy of neurotransmission at the
synapse [53]. Targeted deletion of APP has not revealed a
striking phenotype [54], presumably because of functional
redundancy supplied by APP-like proteins [55]. Mice with
double and triple null mutations in various combinations of
APP, APP-like protein 1, and APP-like protein 2 are now
being created, in search of evidence for a deﬁnitive function
for APP.
Cao and Sudhof [56] have recently discovered that the APP
C-terminal fragment generated by a-o rb-secretase is itself
cleaved to release Ab and an APP intracellular domain
(AICD) that diffuses into the nucleus, possibly acting there as
a transcription factor. The pathway leading to AICD must be
initiated by ectodomain shedding: holoAPP cannot directly
give rise to AICD. Therefore, one important function for a-
and/or b-secretase processing of APP may be the eventual
generation of AICD. Our results suggest that Rho/ROCK
signaling provides modulation of basal and stimulated a-
secretase activity. It will now be important to dissect pathways
upstream of Rho/ROCK signaling in order to identify the
intracellular and intercellular events that participate in Rho/
ROCK regulation of a-secretase under physiological and
pathological conditions.
The potential role of cholesterol in a-secretase-mediated
shedding was discovered by Bodovitz and Klein [57] who used
b-cyclodextrin to lower cellular cholesterol. Kojro et al. [15]
conﬁrmed this observation, using not only b-cyclodextrin but
also lovastatin to lower cellular cholesterol. These investi-
gators proposed that elevated ADAM-10 activity and protein
levels contributed to these effects. These basic observations
dovetailed with emerging epidemiological evidence that
administration of statins might lead to a diminished
incidence of Alzheimer disease [8,9,10,11]. Despite this,
however, the association of statins and cholesterol levels with
activated a-secretase-mediated shedding of the APP ectodo-
main was unexpected and not readily explicable by existing
knowledge regarding regulation of a-secretase activity. The
best characterized regulation of a-secretase processing
typically involves protein phosphorylation via PKC [5,29] or
ERKs [7] or protein dephosphorylation by protein phospha-
tase 1 or 2A [29]. We recently excluded the possibility that
either PKC or ERK plays a role in statin-activated shedding
[16], raising the possibility that other protein phosphoryla-
tion signaling pathways might link statins and/or cholesterol
to a-secretase activation.
Maillet et al. [58] implicated the Rho pathway in modu-
lation of a-secretase activity while dissecting the activated
shedding process that accompanies serotonergic signal trans-
duction. These investigators discovered that Rap1 acts
through Rac to modulate a-secretase processing of APP.
Soon thereafter, ROCK1 was discovered by Zhou et al. [28] to
modulate a downstream processing step in APP metabolism
that involves presenilin/c-secretase-mediated proteolysis of
APP C-terminal fragments C99 and C83. These investigators
Figure 6. Arachidonic Acid Inhibits Basal sAPPa Shedding but Has No
Effect on holoAPP Levels
(A) SweAPP cells were treated for 24 h with arachidonic acid (5 or 50
lM, represented by AA5 and AA50, respectively). Levels of sAPPa
were evaluated by immunoblot as described in Methods. C, control.
(B) Graphic representation of data. Y-axis shows effect of treatment
(in arbitrary units) divided by effect of untreated control (in arbitrary
units); n = 6 independent experiments; *, p , 0.05 versus control;
Student’s t test.
DOI: 10.1371/journal.pmed.0020018.g006
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ROCK Regulation of Alzheimer APP Sheddingdiscovered that activation of ROCK1 may account for how
nonsteroidal anti-inﬂammatory drugs specify the scissile
bond within the APP transmembrane domain that is cleaved
by presenilin/c-secretase to generate the C-terminus of Ab.
Based on these reports, we asked whether the Rho/ROCK
pathway might play a role in controlling shedding of sAPPa
following statin application.
CA ROCK1 and DN ROCK1 molecules yielded direct and
complementary evidence that ROCK1 was indeed a candidate
for modulation of statin-activated a-secretase action. Further,
we were able to demonstrate that a-secretase activity could be
modulated by molecules further upstream in the isoprenoid
pathway (see Figure 7). FTI-1, an inhibitor of farnesyl
transferase also known as L-744,832 [59], mimicked and
potentiated statin-activated shedding, presumably by block-
ing transfer of isoprenoid moieties to a Rho protein by
farnesyl transferase, and thereby decreasing Rho activity.
However, FTI-1 treatment can also increase the level of
geranylgeranylated isoforms of certain Rho proteins, e.g., the
inhibitory geranylgeranylated RhoB protein [60]. In further
support of a role for isoprenoids, we were able to
demonstrate that supplementation of cells with mevalonate
abolished statin-activated shedding (see Figure 4). Statins
block HMGCoA reductase generation of mevalonate from 3-
hydroxy-methyl-glutarate (see Figure 7). Therefore, the
addition of mevalonate would be predicted to antagonize
statin action via the isoprenoid pathway, by relieving statin-
induced mevalonate deﬁciency. As predicted by this model,
we observed that statin-activated shedding was abolished by
adding mevalonate. Taken together, these results suggest the
existence of a reciprocal relationship between isoprenoid-
mediated Rho/ROCK signaling and sAPPa shedding, i.e.,
activation of ROCK1 blocks basal and stimulated shedding
while ROCK1 inhibition apparently relieves a tonic negative
inﬂuence exerted on shedding by ROCK1 activity.
As in PKC- and ERK-activated shedding, the ROCK1
substrate effector molecule or molecules that regulate
proteolysis by ADAMs remain to be identiﬁed. The cytoplas-
mic domains of both APP and ADAM-17 have been evaluated
as candidates for important targets of protein phosphoryla-
tion during the regulated shedding process, but neither
‘‘substrate activation’’ nor ‘‘enzyme activation’’ appears to
explain the phenomenon, i.e., phosphorylation of neither
APP nor ADAM-17 dramatically increases the efﬁciency of a-
secretion [61,62], indicating that activation is more indirect.
Our data using statins and PO localize the mediator of
statin-activated shedding to the plasma membrane, upstream
of endocytosis, as appears to be the case for PKC-activated
shedding [36,63,64,65]. Similar conclusions were drawn by
Bosenberg and colleagues [36] who used streptolysin-porated
cells and N-ethylmaleimide to demonstrate that reconstitu-
tion of activated shedding of TGFa from CHO cells does not
require membrane trafﬁcking and apparently occurs on the
plasma membrane. These results suggest that a tightly
membrane-associated regulatory subunit of the a-secretase
complex is likely to be the key phosphoprotein that mediates
a-secretase activity as a function of its state of phosphor-
ylation by PKC and perhaps also ERK and ROCK1. The
molecular identity of this phosphoprotein remains unknown.
a-Secretase activation is a potential therapeutic strategy
for modifying cerebral amyloidosis in Alzheimer disease [66].
This proposal is supported by recent evidence that either
genetic modiﬁcation of ADAM-10/a-secretase activity [67] or
administration of bryostatin, a PKC activator [68], can
modulate levels of brain Ab in plaque-forming transgenic
mice. a-Secretase activation may explain how statins lower
the risk for Alzheimer disease [69], since atorvastatin
diminishes Ab burden in plaque-forming transgenic mice
[13]. If a-secretase stimulation is to be truly viable as a human
clinical intervention, it will be essential to assess the
possibility that enhanced APP ectodomain shedding might
incur mechanism-based toxicity (analogous to the concerns
currently surrounding c-secretase inhibitors). Along this line,
extension of this work to other shed proteins will be
important to determine the impact of enhanced shedding
via ADAM proteinases on other substrates of those protei-
nases, including Notch, pro-TGFa, pro-TNFa, and CD44 [3].
Preliminary results from a pilot proof-of-concept using
atorvastatin in a human clinical treatment trial are consistent
with the proposed beneﬁcial effects of this class of com-
pounds [70]. Since atorvastatin has low blood–brain barrier
permeability [71], this beneﬁcial effect, if attributable to Ab
lowering, must be due to altered Ab metabolism in the
periphery. Reduction in levels of free Ab in the circulation
has been demonstrated to lead to diminution in brain plaque
burden following active or passive immunization [72]. It is
conceivable that, if statins lower circulating Ab, this effect
could secondarily cause diffusion of central nervous system
interstitial Ab down its concentration gradient and into the
cerebrospinal ﬂuid and circulation, from which it is cleared.
To date, however, this mechanism is not supported by data
from human clinical trials, where statin administration has
shown no consistent effect on levels of circulating or
cerebrospinal ﬂuid Ab [73].
The results reported here point to several areas for
additional investigation. As described above, the key substrate
or substrates linking cytoplasmic protein phosphorylation to
intralumenal or cell-surface protelysis remain to be identi-
ﬁed. Nonetheless, a-secretase activation has been validated as
a viable therapeutic strategy for modulating cerebral amy-
Figure 7. Isoprenoid Pathway and Sites of Action of Compounds Used in
This Study
FPP, farnesyl pyrophosphate; GGPP, geranylgeranyl pyrophosphate.
DOI: 10.1371/journal.pmed.0020018.g007
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ROCK Regulation of Alzheimer APP Sheddingloidosis [67]. Identiﬁcation of the role of the Rho/ROCK
pathway in regulating a-secretase provides a new avenue for
its therapeutic activation, even though the potential rele-
vance of atorvastatin-mediated ROCK1 inhibition in neurons
may not explain the apparent clinical beneﬁts of the drug.
Still, if the reported disease-modifying effect of atorvastatin is
conﬁrmed in the National Institute on Aging’s large, multi-
center trial of simvastatin, one or more compounds of this
class may be among the ﬁrst disease-modifying compounds
approved by the Food and Drug Administration for slowing
the progression of Alzheimer disease.
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Patient Summary
Background Large-scale studies have found a link between taking
cholesterol-lowering drugs called statins and a decreased risk of
developing Alzheimer disease. But it is not clear why statins might
protect people from getting the disease. The brains of people who have
died from Alzheimer disease show remnants of damaged cells called
‘‘tangles’’ as well as ‘‘amyloid plaques’’ in the spaces between the cells.
These plaques are mostly made up of collections of a protein called
amyloid-beta. It is the buildup of this protein that is thought to cause the
brain damage and dementia associated with Alzheimer disease. The
protein itself is formed when another, larger protein called APP
(Alzheimer amyloid-beta peptide precursor protein) is broken down (or
cleaved). There are two ways in which APP can be broken down. ‘‘Bad
cleavage’’ releases the toxic amyloid-beta, whereas ‘‘good cleavage’’
destroys it. When researchers gave statins to animals over a long period
of time, they found that statins could slow down the formation of
amyloid plaques. From the animal experiments, it seemed that statins
somehow caused more good cleavage to occur.
Why Was This Study Done? This study examined how statins can affect
APP cleavage.
What Did the Researchers Do? They studied cells to see which of the
players known to be involved in APP cleavage were affected by statin.
What Did They Find? Statin’s ability to promote ‘‘good cleavage’’ of
APP involves a molecular pathway called the Rho/ROCK1 pathway. It
seems that when ROCK1 is active, less good cleavage takes place. But in
the presence of statins, ROCK1 is less active, shifting the balance toward
good cleavage. Consistent with this, when the scientists blocked the Rho/
ROCK1 pathway, they saw the good cleavage pattern even without statin.
What Does This Mean for Patients? Inhibition of the Rho/ROCK1
pathway could explain some of the beneficial effects of statins against
Alzheimer disease. And the pathway itself seems worth more research to
see whether it might be a good target for new ways to prevent and treat
Alzheimer disease.
What Are the Limitations of the Study? Statins are likely to influence
the risk for Alzheimer disease by several different pathways, and future
studies will need to show how important this particular pathway is in the
overall picture. Moreover, studies like this one are by necessity done in
cells under carefully controlled laboratory conditions and still a long way
from the development of safe and effective drugs.
More Information Online
Factsheet on statins from the Alzheimer’s Association: http://www.alz.
org/Resources/TopicIndex/statins.asp
General information at the Alzheimer’s Disease Education and Referral
Center at the United States National Institute of Aging: http://
www.alzheimers.org/index.html
Homepage of Alzheimer’sDisease International, an umbrella organization
of Alzheimer disease associations around the world: http://www.alz.
co.uk/
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